HEALWELL AI to Announce Fiscal Third Quarter 2025 Financial Results on November 6, 2025
Toronto, Ontario--(Newsfile Corp. - October 27, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to ann
Technology, Healthcare and Hospitals
2025-10-27 5:08 PM EDT | HEALWELL AI
IR-MED's Key Clinical and Media Milestones
Rosh Pina, Israel--(Newsfile Corp. - October 27, 2025) - IR-Med Inc. (OTCQB: IRME), (the "Company" or "IR-Med"), a medical technology company developing a non-invasive, AI-powered infrared spectroscopy platform for the assessment of pressure injuries and diabetic ulcers, today announced a series of recent milestones that highlight the Company's expanding visibility within the healthcare, investment, and media communities. Podium Presentation at Magnet & Pathway 2025 Confer
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-10-27 4:05 PM EDT | IR-MED, Inc.
Wellgistics Health Enters into Smart Contract Services Agreement with DataVault AI to Develop Patented PharmacyChain(TM) Manufacturer-to-Patient Blockchain-Enabled Tracking & Dispensing Platform for Prescription Drug Market
Florida and Philadelphia, Pennsylvania--(Newsfile Corp. - October 27, 2025) - Wellgistics Health, Inc. (NASDAQ: WGRX) ("Wellgistics"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that it has entered into a software as a service (SAAS) agreement with DataVault AI, Inc. (NASDAQ: DVLT) ("DataVault"), a pioneering technology company leading the way in AI data experie
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Blockchain
2025-10-27 9:42 AM EDT | Wellgistics Health
Envoy Medical Receives Positive Listing Determination from NASDAQ
White Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the Nasdaq Hearings Panel (the "Panel) has granted the Company's request for continued listing on the Nasdaq Stock Market. In granting the extension, the Panel considered several key developments, including Envoy Medical's recent equity capital raises and debt e
Biotechnology, Healthcare and Hospitals
2025-10-27 8:00 AM EDT | Envoy Medical, Inc.
HEALWELL Files Amended Business Acquisition Report
Toronto, Ontario--(Newsfile Corp. - October 24, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, announces it has filed an amended and restated business acquisition report dated October 24, 2025 (the "Amended BAR"), relating to HEALWELL's acquisition of Orion Health Holdings Limited which closed on April 1, 2025. The Amended BAR replaces and supersedes the previous
Technology, Healthcare and Hospitals
2025-10-24 7:06 PM EDT | HEALWELL AI
CareRx Corporation to Host Third Quarter 2025 Financial Results Conference Call on Tuesday, November 4, 2025 at 8:30 a.m. ET
Toronto, Ontario--(Newsfile Corp. - October 24, 2025) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company") today announced it will host a conference call to discuss its third quarter 2025 financial results on Tuesday, November 4, 2025, at 8:30 a.m. Eastern Time (ET). The Company expects to report its third quarter 2025 financial results for the period ended September 30, 2025, after market close on Monday, November 3, 2025. Telephone Dial-In Access In
2025-10-24 7:30 AM EDT | CareRx Corporation
HEALWELL AI Completes Week of Business Development and Investor Awareness Activities in the UK Highlighting Its AI-Driven Preventative Healthcare Solutions
HEALWELL AI's management team met with prospective investors, partners and M&A targets as part of a business development roadshow in the UK. HEALWELL also successfully hosted an invitation-only event in London on October 14, 2025, bringing together healthcare leaders, investors, and financial institutions. With strong attendance from UK banks, healthcare providers, and institutional investors, HEALWELL's management shared insights on the growth
Technology, Healthcare and Hospitals
2025-10-23 3:15 AM EDT | HEALWELL AI
Bachem Announces Progress in Building K Start-Up and Expansion of Its Site in Vista, CA
Bubendorf, Switzerland--(Newsfile Corp. - October 23, 202
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-10-23 1:01 AM EDT | Bachem Holding AG
FendX Files Provisional Patent for Novel Antimicrobial Nanoparticle Liquid Coating
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce the filing of a provisional patent application with the United States Patent and Trademark Office. The application, titled "Antimicr
Technology, Healthcare and Hospitals, Health
2025-10-22 6:00 AM EDT | FendX Technologies Inc.
NewOrg Releases Comprehensive Grant Management Guide to Help Nonprofits Streamline Funding and Reporting
Washington, D.C.--(Newsfile Corp. - October 21, 2025) - NewOrg Management System, Inc., a leading provider of cloud-based data management solutions for nonprofits and government agencies, has released a new resource titled Grant Management Software for Nonprofits — Streamline Funding and Reporting. The guide helps nonprofit leaders improve funding allocation, compliance, and reporting with practical strategies grounded in modern, integrated technology. As grant portfolios e
Computer Software, Healthcare and Hospitals, Housing, Aboriginal / Indigenous
2025-10-21 3:00 PM EDT | NewOrg Management System Inc
Adia Nutrition Inc. Appoints Dr. Evan Thomas, MD, PhD, to Drive Adia Med's Specialized Treatment Revolution
Winter Park, Florida--(Newsfile Corp. - October 21, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is excited to announce the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider st
Healthcare and Hospitals, Health
2025-10-21 9:00 AM EDT | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-21 7:45 AM EDT | Phio Pharmaceuticals Corp.
HEALWELL's DARWEN(TM) AI Platform Demonstrates One of the World's First Examples of Using AI to Generate Regulatory-Grade Real-World Data (RWD) for Supporting Patient Access and Advancing the Pharmaceutical Industry
HEALWELL, in collaboration with Takeda Pharmaceutical, presented new AI generated and regulatory-grade real-world data (RWD) on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at the prestigious United European Gastroenterology (UEG) Week in Berlin on October 6, 2025. HEALWELL's DARWEN™ AI platform generated real-world data (RWD) demonstrating that vedolizumab dose escalation from every 8 weeks to every 4 weeks improved
Technology, Healthcare and Hospitals
2025-10-21 3:15 AM EDT | HEALWELL AI
Cosmo Pharmaceuticals Receives Regulatory Approval by the European Commission for Winlevi(R) in the EU, Following on the Positive CHMP Opinion
Dublin, Ireland--(Newsfile Corp. - October 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Commission has granted regulatory approval in the EU for Winlevi® (clascoterone 1% cream) for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years, with usage in adolescents limited to facial application. This formal approval came following on the po
Healthcare and Hospitals, Health
2025-10-21 1:36 AM EDT | Cosmo Pharmaceuticals N.V.
Adaptimmune Announces Delisting from Nasdaq
Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determined to initiate the delisting of its American Depositary Shares ("ADSs"), each representing six ordinary shares, from The Nasdaq Capital Market ("Nasdaq") and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (th
Biotechnology, Healthcare and Hospitals
2025-10-20 7:40 AM EDT | Adaptimmune Therapeutics PLC
MyndTec Inc. Completes Sixth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - October 16, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the sixth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The sixth tranche of the private placement consists of 263,428 Units of the Company (the "Units") at a price of $0.20 per Uni
Technology, Healthcare and Hospitals, Health
2025-10-16 6:00 PM EDT | MyndTec Inc.
Conexeu Sciences Closes Maximum $5M Reg CF Financing
Reno, Nevada--(Newsfile Corp. - October 16, 2025) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a biotechnology company revolutionizing tissue regeneration, is pleased to announce the completion of its $5 million Regulation Crowdfunding (Reg CF) financing. Conexeu secured commitments in excess of $5 million in less than two weeks from the date of launching the financing through the Equifund platform.
Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-16 9:01 AM EDT | Conexeu Sciences Inc.
Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 Submission
Winter Park, Florida--(Newsfile Corp. - October 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is thrilled to announce a major milestone in its growth journey. The Company has engaged an independent public accounting firm and securities counsel to prepare and file its Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). This filing marks a significant step beyond OTC reporting and positions Adia as a fully reporting public company under the Securities Exchange
Healthcare and Hospitals, Health
2025-10-14 9:00 AM EDT | Adia Nutrition Inc.
Envoy Medical Announces Closing of Up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
White Bear Lake, Minnesota--(Newsfile Corp. - October 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 3,007,524 shares of its Class A common stock at a purchase price of $1.33 per share. In addition, in a concurrent private placement, Envoy Medical issued
Biotechnology, Healthcare and Hospitals
2025-10-09 4:05 PM EDT | Envoy Medical, Inc.
Global Hemp Group Applies for Partial Revocation Order and Announces Proposed Financing
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG0) ("GHG" or the "Company") announces that it has applied to the British Columbia Securities Commission ("BCSC") for a partial revocation order (the "Partial Revocation Order") in connection with the failure-to-file cease trade order ("FFCTO") issued against the Company on April 15, 2025, for failing to file certain continu
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Cannabis
2025-10-09 9:29 AM EDT | Global Hemp Group Inc.